Increased sulfiredoxin-1 levels as compensatory mechanism against reactive oxygen species in women with gestational diabetes mellitus Gestasyonel diabetes mellituslu kadınlarda reaktif oksijen türlerine karşı telafi edici bir mekanizma olarak sülfiredoksin-1 düzeyleri artmaktadır
Turkish Journal of Obstetrics and Gynecology, cilt.18, sa.4, ss.267-271, 2021 (ESCI, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 18 Sayı: 4
- Basım Tarihi: 2021
- Doi Numarası: 10.4274/tjod.galenos.2021.26053
- Dergi Adı: Turkish Journal of Obstetrics and Gynecology
- Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.267-271
- Anahtar Kelimeler: Sulfiredoxin-1, gestational diabetes mellitus, pregnancy, peroxiredoxin, reactive oxygen species
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objective: This study aimed to investigate the correlation between serum Sulfiredoxin-1 (Srx-1) levels and gestational diabetes mellitus (GDM). Materials and Methods: A total of 40 patients diagnosed with GDM according to the American Diabetes Association Criteria and 40 age matched and gestational age-matched healthy pregnant women as a control group were included in this cross-sectional study. Serum Srx-1 levels and other demographic and laboratory variables were analyzed. Results: Fasting plasma glucose, first and second-hour plasma glucose levels, fasting insulin levels, homeostasis model assessment of insulin resistance (HOMA-IR), and Srx-1 levels were significantly different in patients with GDM than control (p<0.05). Plasma Srx-1 levels significantly correlated with fasting plasma glucose, first and second-hour plasma glucose levels, fasting insulin levels, and HOMA-IR of patients with GDM (p<0.05), whereas no correlation in the control group. Conclusion: This is the first study demonstrating an association between serum Srx-1 levels and GDM. Our results suggest increased serum Srx-1 levels may be a novel predictive marker for GDM. More randomized-controlled trials are needed to evaluate Srx-1 as a marker for adverse fetal results; closer monitoring is warranted with high Srx-1 levels.